Distal Access Release: New “See-and-Treat” Tissue Resection System Cleared To Sell In The U.S.A.

PARK CITY, Utah--(BUSINESS WIRE)--Distal Access announced that they completed FDA registration for the RESECTR™ 9 French / 3.0mm High-Performance Disposable Tissue Resector allowing the company to begin sales in the United States.

“Patient safety always comes first. So, we innovated a non-powered and hand-held manual surgical instrument controlled by the physician’s hand”

Soft tissue resection is performed throughout the body. The procedure typically involves inserting a small metal cannula with rotating internal cutting blades up against tissue then actuating the cutting blades with an electromechanical motor to cut and aspirate tissue. Physicians typically give up “feel” and “control” when using electromechanical systems.

“Patient safety always comes first. So, we innovated a non-powered and hand-held manual surgical instrument controlled by the physician’s hand,” said Chris Livingstone, VP Sales & Marketing of Distal Access. “Clinicians can increase or decrease tissue resection speed and aspiration based on what they see and feel during the procedure.”

Electromechancial systems are expensive. These systems require the hospital, clinic, or office to buy complex and expensive capital equipment then pay $500 – $1,000+ per patient for single-patient-use disposables. Many clinics and offices can’t afford electromechanical capital equipment or disposables.

“Electromechanical systems are complex and expensive with limited availability outside of hospitals,” continued Livingstone. “The RESECTR High-Performance Disposable Tissue Resector shows up ‘ready-to-use’ at the hospital, clinic, or office. Complex expensive capital equipment is not needed and the disposables cost less than other systems.”

Certain tissue resection systems are used as accessories to hysteroscopes during uterine polyp removal. Clinicians surveyed at the American Congress of Obstetricians and Gynecologists (ACOG) and European Society for Gynaecological Endoscopy (ESGE) expressed a strong need for a system that allows clinicians to “see-and-treat” lesions in one setting to improve patient comfort and care.

“Many patients are lost in follow up between office diagnosis and hospital treatment. Those patients live with pain and other complications,” added Livingstone. “The RESECTR platform gives clinicians an important tool to ‘see-and-treat’ lesions in a variety of clinical settings where it is best for the patient’s care.”

According to the company, the RESECTR technology may allow patients to be treated earlier, many in the office, to alleviate pain and remove lesions before they are allowed to grow.

The RESECTR is manufactured in the USA for Distal Access, Park City, Utah. RESECTRs are protected by 12 issued and pending patents. For more information about the RESECTR, call 1-954-534-9345 or visit www.RESECTR.com.